APOE and Alzheimer disease: Additionally, individual BrainAGE scores were profoundly related to measures of clinical disease severity, most pronounced in APOE ε4 carriers and non-carriers already diagnosed with AD at baseline, as well as to measures of cognitive functioning, most pronounced in APOE ε4 carriers diagnosed with MCI at baseline and converting to AD within the next three years.